RNAi Therapeutics News and Research

RSS
RNA interference (RNAi) was discovered less than a decade ago and already there are human clinical trials in progress or planned. A major advantage of RNAi versus other anti-sense based approaches for therapeutic applications is that it utilizes cellular machinery that efficiently allows targeting of complementary transcripts, often resulting in highly potent down-regulation of gene expression.
RBSC announces partnership with Mitacs to develop and test yeast-based RNAi technology

RBSC announces partnership with Mitacs to develop and test yeast-based RNAi technology

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

EC grants marketing authorization for ONPATTRO (patisiran) in Europe

EC grants marketing authorization for ONPATTRO (patisiran) in Europe

Alnylam’s patisiran receives positive opinion from CHMP for treating hATTR amyloidosis

Alnylam’s patisiran receives positive opinion from CHMP for treating hATTR amyloidosis

Alnylam announces new positive results from Phase 1/2 study of lumasiran in patients with PH1

Alnylam announces new positive results from Phase 1/2 study of lumasiran in patients with PH1

Alnylam achieves delivery of novel siRNAs conjugates to the central nervous system

Alnylam achieves delivery of novel siRNAs conjugates to the central nervous system

Regeneron forms consortium to accelerate largest widely-available human sequencing resource

Regeneron forms consortium to accelerate largest widely-available human sequencing resource

Alnylam reports new results from investigational RNAi therapeutic programs

Alnylam reports new results from investigational RNAi therapeutic programs

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Trends, R&D progress, and predicted revenues in RNAi therapies

Trends, R&D progress, and predicted revenues in RNAi therapies

Alnylam presents positive Phase 1 ALN-AT3 trial results in hemophilia at ISTH 2015 Congress

Alnylam presents positive Phase 1 ALN-AT3 trial results in hemophilia at ISTH 2015 Congress

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Alnylam announces clinical data from patisiran Phase 2 OLE study for treatment of patients with FAP

Alnylam announces clinical data from patisiran Phase 2 OLE study for treatment of patients with FAP

Sirnaomics submits STP705 IND Application to CFDA for skin scar treatment

Sirnaomics submits STP705 IND Application to CFDA for skin scar treatment

Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Arrowhead Research joins with broad-market Russell 3000 Index

Arrowhead Research joins with broad-market Russell 3000 Index

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases